Cabaletta Bio, Inc. $CABA

What the company doesAI summary of filing

Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. The company's lead product candidate, resecabtagene autoleucel (rese-cel), is a CD19-targeting CAR T cell therapy designed to deplete B cells and reset the immune system, currently being evaluated in Phase 1/2 trials across multiple autoimmune indications including systemic lupus erythematosus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. Cabaletta is pre-revenue and plans to generate revenue through the commercial sale of rese-cel if regulatory approval is obtained; the company has incurred significant losses since inception and states it anticipates continuing to incur significant losses for the foreseeable future while it advances clinical development and seeks regulatory approval. [10-K 2026-03-23]

Segments: Rese-cel (resecabtagene autoleucel) for systemic lupus erythematosus, Rese-cel for myositis, Rese-cel for systemic sclerosis, Rese-cel for myasthenia gravis and pemphigus vulgaris